Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

被引：201
作者：
Mithoowani, Hamid [1 ]
Febbraro, Michela [2 ]
机构：
[1] Grand River Reg Canc Ctr, 835 King St W, Kitchener, ON N2G 1G3, Canada
[2] Hamilton Hlth Sci Ctr, Juravinski Canc Ctr, 699 Concess St, Hamilton, ON L8V 5C2, Canada
来源：
CURRENT ONCOLOGY | 2022年 / 29卷 / 03期
关键词：
non-small cell lung cancer; lung cancer; screening; immunotherapy; iRAE; iRAEs; CAGPO; Canadian Association of General Practitioners in Oncology; ALK; EGFR; K-RAS; KRAS; OPEN-LABEL; SINGLE-ARM; CHEMOTHERAPY; OSIMERTINIB; CHEMORADIOTHERAPY; MULTICENTER; CRIZOTINIB; MUTATIONS; NIVOLUMAB; SELECTION;
D O I：
10.3390/curroncol29030150
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Lung cancer is the leading cause of cancer death in Canada and a significant cause of morbidity for patients and their loved ones. There have been rapid advances in preventing, screening and treating this disease. Here, we present a contemporary review of treatment of non-small cell lung cancer in Canada based on current best practices. The focus of this review is to highlight recent data in screening for lung cancer, management of patients with early and locally-advanced non-small cell lung cancer, as well as management of patients with metastatic disease. There is a special focus on the incorporation of immunotherapy into practice and its associated toxicities.
引用
收藏
页码：1828 / 1839
页数：12
相关论文
共 66 条
  • [1] Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
    Albain, Kathy S.
    Swann, R. Suzanne
    Rusch, Valerie W.
    Turrisi, Andrew T., III
    Shepherd, Frances A.
    Smith, Colum
    Chen, Yuhchyau
    Livingston, Robert B.
    Feins, Richard H.
    Gandara, David R.
    Fry, Willard A.
    Darling, Gail
    Johnson, David H.
    Green, Mark R.
    Miller, Robert C.
    Ley, Joanne
    Sause, Willliam T.
    Cox, James D.
    [J]. LANCET, 2009, 374 (9687) : 379 - 386
  • [2] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    de Castro Carpeno, J.
    Wadsworth, C.
    Melillo, G.
    Jiang, H.
    Huang, Y.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1919 - 1929
  • [3] Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer
    Auperin, Anne
    Le Pechoux, Cecile
    Rolland, Estelle
    Curran, Walter J.
    Furuse, Kiyoyuki
    Fournel, Pierre
    Belderbos, Jose
    Clamon, Gerald
    Ulutin, Hakki Cuneyt
    Paulus, Rebecca
    Yamanaka, Takeharu
    Bozonnat, Marie-Cecile
    Uitterhoeve, Apollonia
    Wang, Xiaofei
    Stewart, Lesley
    Arriagada, Rodrigo
    Burdett, Sarah
    Pignon, Jean-Pierre
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2181 - 2190
  • [4] ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
    Bergethon, Kristin
    Shaw, Alice T.
    Ou, Sai-Hong Ignatius
    Katayama, Ryohei
    Lovly, Christine M.
    McDonald, Nerina T.
    Massion, Pierre P.
    Siwak-Tapp, Christina
    Gonzalez, Adriana
    Fang, Rong
    Mark, Eugene J.
    Batten, Julie M.
    Chen, Haiquan
    Wilner, Keith D.
    Kwak, Eunice L.
    Clark, Jeffrey W.
    Carbone, David P.
    Ji, Hongbin
    Engelman, Jeffrey A.
    Mino-Kenudson, Mari
    Pao, William
    Iafrate, A. John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) : 863 - 870
  • [5] Borghaei H, 2021, J CLIN ONCOL, V39, P723, DOI 10.1200/JCO.20.01605
  • [6] Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer
    Bradley, Jeffrey D.
    Hu, Chen
    Komaki, Ritsuko R.
    Masters, Gregory A.
    Blumenschein, George R.
    Schild, Steven E.
    Bogart, Jeffrey A.
    Forster, Kenneth M.
    Magliocco, Anthony M.
    Kavadi, Vivek S.
    Narayan, Samir
    Iyengar, Puneeth
    Robinson, Clifford G.
    Wynn, Raymond B.
    Koprowski, Christopher D.
    Olson, Michael R.
    Meng, Joanne
    Paulus, Rebecca
    Curran, Walter J., Jr.
    Choy, Hak
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (07) : 706 - +
  • [7] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
    Brahmer, Julie R.
    Lacchetti, Christina
    Schneider, Bryan J.
    Atkins, Michael B.
    Brassil, Kelly J.
    Caterino, Jeffrey M.
    Chau, Ian
    Ernstoff, Marc S.
    Gardner, Jennifer M.
    Ginex, Pamela
    Hallmeyer, Sigrun
    Chakrabarty, Jennifer Holter
    Leighl, Natasha B.
    Mammen, Jennifer S.
    McDermott, David F.
    Naing, Aung
    Nastoupil, Loretta J.
    Phillips, Tanyanika
    Porter, Laura D.
    Puzanov, Igor
    Reichner, Cristina A.
    Santomasso, Bianca D.
    Seigel, Carole
    Spira, Alexander
    Suarez-Almazor, Maria E.
    Wang, Yinghong
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Thompson, John A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1714 - +
  • [8] The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients
    Cai, Dongjing
    Hu, Chengping
    Li, Li
    Deng, Shichao
    Yang, Jing
    Han Han-Zhang
    Li, Min
    [J]. CANCER MEDICINE, 2020, 9 (01): : 84 - 93
  • [9] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
    Camidge, D. R.
    Kim, H. R.
    Ahn, M. -J.
    Yang, J. C. -H.
    Han, J. -Y.
    Lee, J. -S.
    Hochmair, M. J.
    Li, J. Y. -C.
    Chang, G. -C.
    Lee, K. H.
    Gridelli, C.
    Delmonte, A.
    Garcia Campelo, R.
    Kim, D. -W.
    Bearz, A.
    Griesinger, F.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S. N.
    Tiseo, M.
    Gupta, N.
    Haney, J.
    Kerstein, D.
    Popat, S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) : 2027 - 2039
  • [10] Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
    Camidge, D. Ross
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James C. H.
    Han, Ji-Youn
    Hochmair, Maximilian J.
    Lee, Ki Hyeong
    Delmonte, Angelo
    Garcia Campelo, Maria Rosario
    Kim, Dong-Wan
    Griesinger, Frank
    Felip, Enriqueta
    Califano, Raffaele
    Spira, Alexander
    Gettinger, Scott N.
    Tiseo, Marcello
    Lin, Huamao M.
    Gupta, Neeraj
    Hanley, Michael J.
    Ni, Quanhong
    Zhang, Pingkuan
    Popat, Sanjay
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3592 - +
1234567